Isomorphic Labs Raises $2.1B for AI Drug Discovery
LONDON — Isomorphic Labs, the Alphabet-backed artificial intelligence drug discovery company, has raised $2.1 billion in new funding to expand its AI-powered pharmaceutical research capabilities, according to a report by Indiatimes.
The funding round represents one of the largest capital raises in the AI-for-science sector.
Isomorphic Labs was founded in 2021 by Demis Hassabis, the Nobel Prize-winning CEO of Google DeepMind, as a standalone Alphabet subsidiary focused on applying AI breakthroughs — including technology derived from the AlphaFold protein structure prediction system — to the drug discovery process.
The company, headquartered in London, has drawn attention from US investors and pharmaceutical partners. Alphabet’s Google remains a primary backer of the venture, and the expansion is expected to include deepened ties with US-based pharmaceutical companies and research institutions.
Isomorphic has previously secured partnerships with major pharmaceutical firms, including deals with Eli Lilly and Novartis announced in 2024 that were collectively valued at nearly $3 billion in potential milestone payments. Those agreements focused on using Isomorphic’s AI platform to identify and design novel drug candidates.
The new capital infusion comes amid a surge of investment into AI-driven drug discovery. The sector has attracted billions in venture capital and strategic funding as pharmaceutical companies look to AI to reduce the cost and time required to bring new therapies to market — a process that traditionally takes more than a decade and costs upward of $2 billion per approved drug.
Alphabet’s sustained investment in Isomorphic positions the company alongside other well-funded AI drug discovery players, including Recursion Pharmaceuticals and Insilico Medicine, as the sector works to demonstrate that AI can improve clinical success rates.
The specific investors participating in the $2.1 billion round and the company’s resulting valuation were not detailed in the initial report.
